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Overview:  
Ovarian cancer is the most common cause of gynaecological cancer death, with an 
overall 5-year relative survival of 43%. Impaired physical wellbeing and overall 
quality of life (QoL) represent major concerns for women during and following 
ovarian cancer treatment, predict survival and are amenable to change through 
interventions. Exercise, now considered an important part of overall management of a 
number of cancers, improves short-term outcomes (e.g., function, fatigue, QoL) 
during chemotherapy. There is also exciting, albeit preliminary data to suggest 
exercise may assist patients to receive the planned dose of chemotherapy without 
delay or dose modifications and may improve survival. The potential quality and 
quantity of life benefits of exercise have not been assessed in women with ovarian 
cancer, despite this group having significant capacity for change in exercise 
behaviour. Therefore, the purpose of the ECHO trial is to evaluate the effects of an 
exercise intervention during first-line adjuvant chemotherapy for epithelial ovarian 
cancer, with outcomes of interest including physical wellbeing, function, QoL, 
chemotherapy-adverse events and adherence and progression-free survival.  Cost-
effectiveness, and potential mechanistic pathways of exercise during chemotherapy 
will also be explored. The ECHO trial is the first randomised trial worldwide to 
ascertain the value of adding exercise to standard chemotherapy for women with 
ovarian cancer and reflects a collaborative effort involving ANZGOG, NHMRC CTC, 
and the Institute of Health and Biomedical Innovation, QUT. Key study design 
features, including outcomes of interest, timing of assessments, recruitment approach, 
intervention details and timeline, will be outlined during the presentation.  
